Cooper Companies sits at the intersection of a perfect four-quarter earnings beat streak and a confirmed technical downtrend; the stock offers thin upside against meaningful downside risk, and the path to a constructive setup runs through a death cross resolution that has not yet occurred.
Thesis pillars
- Death Cross Confirmed Downtrend↓Deteriorating
- Perfect Four Quarter Beat Streak↓Deteriorating
- Thin Upside Unfavorable Risk Reward↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
The Cooper Companies, Inc. (COO) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $75.57 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Overbought (RSI 75).
The Cooper Companies manufactures contact lenses via CooperVision and fertility/women's health devices via CooperSurgical, with products sold in over 130 countries. Approximately half of net sales are derived outside the United States. CooperVision's Biofinity brand is its... Read more
Sell if holding. Analyst target reached at $75.57 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Overbought (RSI 75). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About The Cooper Companies, Inc.
About The Cooper Companies, Inc.
CooperVision's MiSight 1 day lens became the first and only FDA-approved contact lens for slowing myopia progression in children aged 8-12 (approved November 2019), with subsequent approvals from China's NMPA in August 2021 and Japan's MHLW in August 2025. The Cooper Companies operates two segments — CooperVision and CooperSurgical — selling contact lenses, fertility products, and women's health devices across over 130 countries, with approximately half of net sales derived outside the United States.
The Cooper Companies earns revenue through contact lens sales across multiple modalities: single-use lenses under the MyDay and clariti 1 day brands, monthly replacement lenses under the Biofinity brand (the company's highest-grossing product), and two-week replacement under Avaira Vitality. CooperSurgical generates revenue from fertility products — media, micro-tools, and lab equipment — and services including donor gametes, cryostorage, and genomic testing sold through fertility clinics, plus Paragard, a hormone-free copper IUD available exclusively in the United States. CooperVision competes with Johnson & Johnson Vision Care, Alcon, and Bausch + Lomb; CooperSurgical faces competition from Vitrolife Group and Nexpring in fertility and from Hologic in women's health medical devices. Raw material supply for silicone hydrogel lenses including MyDay, Biofinity, Avaira, and clariti comes from few or sole suppliers.
Show full overview
Supplier dependence for silicone hydrogel lens materials is the most concrete supply chain risk in the filing: some primary materials for MyDay, Biofinity, Avaira, and clariti come from 'few or sole suppliers.' CooperVision manufactures primarily at facilities in Costa Rica, Hungary, Puerto Rico, the United Kingdom, and the United States; the 10-K discloses that certain products are approved for manufacturing at only one manufacturing site for certain markets, meaning a prolonged facility disruption could require significant time — potentially years — for regulatory validation of an alternative, with inventory backup limited for products with short shelf lives.
See also: Healthcare · Medical Instruments & Supplies
From The Cooper Companies, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-08-15Recent Developments — The Cooper Companies, Inc.
Latest news
- NEWS Is It Time To Consider Buying The Cooper Companies, Inc. (NASDAQ:COO)? - 富途牛牛 — 富途牛牛 positive
- NEWS A Look at The Cooper Companies Inc (COO) After 3.2% Decline -- G - GuruFocus — GuruFocus negative
- NEWS The Cooper Companies grows its healthcare footprint. Vision and fertility drive long-term demand - Ad-hoc-news.de — Ad-hoc-news.de positive
- NEWS The Cooper Companies highlights eye care growth as investors watch US exposure - Ad-hoc-news.de — Ad-hoc-news.de positive
- NEWS The Cooper Companies Q2 2026 earnings preview - MSN — MSN neutral
Generated 2026-08-15T11:27:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $75.57 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Overbought (RSI 75). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $72.83. Score 5.2/10, moderate confidence.
Take-profit target: $87.60 (-7.2% upside). Prior stop was $72.83. Stop-loss: $72.83.
Analyst target reached - limited upside remaining; Overbought (RSI 75).
The Cooper Companies, Inc. trades at a P/E of 64.9 (forward 15.3). TrendMatrix value score: 4.5/10. Verdict: Sell.
23 analysts cover COO with a consensus score of 3.8/5. Average price target: $81.
What does The Cooper Companies, Inc. do?The Cooper Companies manufactures contact lenses via CooperVision and fertility/women's health devices via...
The Cooper Companies manufactures contact lenses via CooperVision and fertility/women's health devices via CooperSurgical, with products sold in over 130 countries. Approximately half of net sales are derived outside the United States. CooperVision's Biofinity brand is its highest-grossing product; CooperSurgical's portfolio includes Paragard IUD, IVF media and tools, and donor gamete cryostorage.